Worth reading
50Recurring
Scored from 3 of 6 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
13015
million yenWording
Avoiding a definitive answer
How definitive the wording is.Contents of this document
Supplementary materials to the earnings reportFY2026.3 Financial Results2 items taken from the company’s own explanation
What the company explained in this material
Key KPIsA metric the company considers important as a management benchmark.
- Order backlog13,015 million yenYear on year against the same period last yearUp 10.9%
Orders received and order backlog
Order backlog13,015 million yen
Record date22 May 2026
| Item | Details |
|---|---|
| Document type | Supplementary materials to the earnings report |
| Fiscal Period Covered | FY2026.3 Financial Results |
| Key KPIs | Indicator name Order backlog / Value 13,015 million yen / Year on year against the same period last year Up 10.9% |
| Orders received and order backlog | Order backlog 13,015 million yen / Record date 22 May 2026 |
Items this document does not state (27)
Net SalesOperating profitOrdinary incomeNet incomeGross Profit MarginOperating profit marginSelling, general and administrative expensesResults for the three months of the current quarterFull-year earnings forecastProgress against full-year forecastSelf-assessment against the planSegment resultsBreakdown of Factors Affecting the ChangeUnit price and quantity metricsNumber of stores and locationsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresMarket Size / ShareKey points of the Q&ANew initiatives
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The order backlog was updated to reflect the completion of the 2 contracts that had been undergoing execution procedures, as well as the completion of contracts for international joint clinical trials and new projects, and contract changes for existing projects.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.